{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:29:30Z","timestamp":1773152970869,"version":"3.50.1"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T00:00:00Z","timestamp":1321315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1038\/nrrheum.2011.168","type":"journal-article","created":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T14:51:17Z","timestamp":1321368677000},"page":"13-21","source":"Crossref","is-referenced-by-count":44,"title":["Cardiovascular safety of biologic therapies for the treatment of RA"],"prefix":"10.1038","volume":"8","author":[{"given":"Jeffrey D.","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Furer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,15]]},"reference":[{"key":"BFnrrheum2011168_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","volume":"107","author":"DH Solomon","year":"2003","unstructured":"Solomon, D. H.  et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303\u20131307 (2003).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR2","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/art.23811","volume":"58","author":"F Wolfe","year":"2008","unstructured":"Wolfe, F. & Michaud, K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case\u2013control analysis. Arthritis Rheum. 58, 2612\u20132621 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR3","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1136\/ard.2005.050377","volume":"65","author":"DH Solomon","year":"2006","unstructured":"Solomon, D. H.  et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1608\u20131612 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR4","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","volume":"48","author":"C Meune","year":"2009","unstructured":"Meune, C., Touze, E., Trinquart, L. & Allanore, Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 48, 1309\u20131313 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2011168_CR5","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685\u20131695 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2011168_CR6","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","volume":"108","author":"N Sattar","year":"2003","unstructured":"Sattar, N., McCarey, D. W., Capell, H. & McInnes, I. B. Explaining how \u201chigh-grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 2957\u20132963 (2003).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1161\/01.CIR.100.13.1481","volume":"100","author":"SM Grundy","year":"1999","unstructured":"Grundy, S. M., Pasternak, R., Greenland, P., Smith, S. Jr & Fuster, V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100, 1481\u20131492 (1999).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR8","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","volume":"44","author":"ID del Rincon","year":"2001","unstructured":"del Rincon, I. D., Williams, K., Stern, M. P., Freeman, G. L. & Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44, 2737\u20132745 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR9","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1136\/ard.2009.122226","volume":"69","author":"DH Solomon","year":"2010","unstructured":"Solomon, D. H.  et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann. Rheum. Dis. 69, 1920\u20131925 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR10","first-page":"435","volume":"32","author":"PH Dessein","year":"2005","unstructured":"Dessein, P. H.  et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol. 32, 435\u2013442 (2005).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011168_CR11","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1002\/art.21397","volume":"52","author":"I del Rincon","year":"2005","unstructured":"del Rincon, I., Freeman, G. L., Haas, R. W., O'Leary, D. H. & Escalante, A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 52, 3413\u20133423 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova, E.  et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann. Rheum. Dis. 70, 482\u2013487 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jbspin.2010.07.016","volume":"78","author":"JF Boyer","year":"2011","unstructured":"Boyer, J. F., Gourraud, P. A., Cantagrel, A., Davignon, J. L. & Constantin, A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 78, 179\u2013183 (2011).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum2011168_CR14","first-page":"430","volume":"32","author":"C Book","year":"2005","unstructured":"Book, C., Saxne, T. & Jacobsson, L. T. Prediction of mortality in rheumatoid arthritis based on disease activity markers. J. Rheumatol. 32, 430\u2013434 (2005).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011168_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/art.20878","volume":"52","author":"H Maradit-Kremers","year":"2005","unstructured":"Maradit-Kremers, H., Nicola, P. J., Crowson, C. S., Ballman, K. V. & Gabriel, S. E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 52, 722\u2013732 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR16","first-page":"943","volume":"34","author":"PH Dessein","year":"2007","unstructured":"Dessein, P. H., Norton, G. R., Woodiwiss, A. J., Joffe, B. I. & Wolfe, F. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J. Rheumatol. 34, 943\u2013951 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011168_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/1529-0131(200105)44:5<1170::AID-ANR200>3.0.CO;2-T","volume":"44","author":"LT Jacobsson","year":"2001","unstructured":"Jacobsson, L. T.  et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum. 44, 1170\u20131176 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR18","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/art.11024","volume":"48","author":"F Wolfe","year":"2003","unstructured":"Wolfe, F., Michaud, K., Gefeller, O. & Choi, H. K. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum. 48, 1530\u20131542 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/ard.2006.056390","volume":"66","author":"TM Farragher","year":"2007","unstructured":"Farragher, T. M., Lunt, M., Bunn, D. K., Silman, A. J. & Symmons, D. P. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann. Rheum. Dis. 66, 486\u2013492 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/ard.2006.052506","volume":"66","author":"C Turesson","year":"2007","unstructured":"Turesson, C., McClelland, R. L., Christianson, T. J. & Matteson, E. L. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 70\u201375 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR21","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/art.11078","volume":"48","author":"I Del Rincon","year":"2003","unstructured":"Del Rincon, I.  et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum. 48, 1833\u20131840 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR22","first-page":"2562","volume":"26","author":"S Wallberg-Jonsson","year":"1999","unstructured":"Wallberg-Jonsson, S., Johansson, H., Ohman, M. L. & Rantapaa-Dahlqvist, S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J. Rheumatol. 26, 2562\u20132571 (1999).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011168_CR23","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/art.21204","volume":"52","author":"NJ Goodson","year":"2005","unstructured":"Goodson, N. J.  et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 52, 2293\u20132299 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR24","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/art.25009","volume":"61","author":"YH Rho","year":"2009","unstructured":"Rho, Y. H.  et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 61, 1580\u20131585 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR25","first-page":"45","volume":"20","author":"D van Schaardenburg","year":"1993","unstructured":"van Schaardenburg, D.  et al. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J. Rheumatol. 20, 45\u201352 (1993).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011168_CR26","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1002\/art.10419","volume":"46","author":"NJ Goodson","year":"2002","unstructured":"Goodson, N. J.  et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 46, 2010\u20132019 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3899\/jrheum.080322","volume":"35","author":"A Gonzalez","year":"2008","unstructured":"Gonzalez, A.  et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J. Rheumatol. 35, 1009\u20131014 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011168_CR28","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.3899\/jrheum.090188","volume":"36","author":"KP Liang","year":"2009","unstructured":"Liang, K. P.  et al. Autoantibodies and the risk of cardiovascular events. J. Rheumatol. 36, 2462\u20132469 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011168_CR29","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1136\/ard.2009.110536","volume":"69","author":"G Tomasson","year":"2010","unstructured":"Tomasson, G.  et al. Effect of rheumatoid factor on mortality and coronary heart disease. Ann. Rheum. Dis. 69, 1649\u20131654 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/0003319710366124","volume":"61","author":"DF Burut","year":"2010","unstructured":"Burut, D. F., Karim, Y. & Ferns, G. A. The role of immune complexes in atherogenesis. Angiology 61, 679\u2013689 (2010).","journal-title":"Angiology"},{"key":"BFnrrheum2011168_CR31","first-page":"281","volume":"24","author":"N del Val del Amo","year":"2006","unstructured":"del Val del Amo, N., Ibanez Bosch, R., Fito Manteca, C., Gutierrez Polo, R. & Loza Cortina, E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin. Exp. Rheumatol. 24, 281\u2013286 (2006).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2011168_CR32","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/ard.2007.073718","volume":"67","author":"R Gerli","year":"2008","unstructured":"Gerli, R.  et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann. Rheum. Dis. 67, 724\u2013725 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/art.24390","volume":"61","author":"FJ Lopez-Longo","year":"2009","unstructured":"Lopez-Longo, F. J.  et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 61, 419\u2013424 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR34","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/art.1780301102","volume":"30","author":"PK Gregersen","year":"1987","unstructured":"Gregersen, P. K., Silver, J. & Winchester, R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205\u20131213 (1987).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR35","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S0198-8859(98)00110-4","volume":"60","author":"A Valenzuela","year":"1999","unstructured":"Valenzuela, A.  et al. Association of HLA shared epitope with joint damage progression in rheumatoid arthritis. Hum. Immunol. Mar. 60, 250\u2013254 (1999).","journal-title":"Hum. Immunol. Mar."},{"key":"BFnrrheum2011168_CR36","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0002-9343(03)00133-5","volume":"114","author":"C Gonzalez-Juanatey","year":"2003","unstructured":"Gonzalez-Juanatey, C.  et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am. J. Med. 114, 647\u2013652 (2003).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2011168_CR37","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/art.22527","volume":"56","author":"DL Mattey","year":"2007","unstructured":"Mattey, D. L.  et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum. 56, 1408\u20131416 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/art.23149","volume":"58","author":"TM Farragher","year":"2008","unstructured":"Farragher, T. M.  et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum. 58, 359\u2013369 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR39","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1136\/ard.2010.144634","volume":"70","author":"TE Toms","year":"2011","unstructured":"Toms, T. E.  et al. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 1025\u20131032 (2011).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 1","key":"BFnrrheum2011168_CR40","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.amjmed.2008.06.014","volume":"121","author":"P Libby","year":"2008","unstructured":"Libby, P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am. J. Med. 121 (Suppl. 1), S21\u2013S31 (2008).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2011168_CR41","doi-asserted-by":"publisher","first-page":"R210","DOI":"10.1186\/ar766","volume":"5","author":"A Pawlik","year":"2003","unstructured":"Pawlik, A.  et al. The expansion of CD4+CD28\u2212 T cells in patients with rheumatoid arthritis. Arthritis Res. Ther. 5, R210\u2013R213 (2003).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2011168_CR42","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1161\/01.CIR.0000131450.66017.B3","volume":"109","author":"R Gerli","year":"2004","unstructured":"Gerli, R.  et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109, 2744\u20132748 (2004).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR43","doi-asserted-by":"publisher","first-page":"R984","DOI":"10.1186\/ar1775","volume":"7","author":"KJ Warrington","year":"2005","unstructured":"Warrington, K. J.  et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res. Ther. 7, R984\u2013R991 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2011168_CR44","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1161\/01.CIR.101.25.2883","volume":"101","author":"G Liuzzo","year":"2000","unstructured":"Liuzzo, G.  et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101, 2883\u20132888 (2000).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/rheumatology\/36.2.164","volume":"36","author":"AJ Littler","year":"1997","unstructured":"Littler, A. J.  et al. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br. J. Rheumatol. 36, 164\u2013169 (1997).","journal-title":"Br. J. Rheumatol."},{"key":"BFnrrheum2011168_CR46","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11239-009-0370-y","volume":"29","author":"W Foster","year":"2010","unstructured":"Foster, W., Carruthers, D., Lip, G. Y. & Blann, A. D. Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment. J. Thromb. Thrombolysis 29, 437\u2013442 (2010).","journal-title":"J. Thromb. Thrombolysis"},{"key":"BFnrrheum2011168_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/hy0102.099031","volume":"39","author":"P Boutouyrie","year":"2002","unstructured":"Boutouyrie, P.  et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 39, 10\u201315 (2002).","journal-title":"Hypertension"},{"key":"BFnrrheum2011168_CR48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/art.10748","volume":"48","author":"M Wong","year":"2003","unstructured":"Wong, M.  et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum. 48, 81\u201389 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1161\/01.HYP.0000168055.89955.db","volume":"46","author":"MJ Roman","year":"2005","unstructured":"Roman, M. J.  et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 46, 194\u2013199 (2005).","journal-title":"Hypertension"},{"key":"BFnrrheum2011168_CR50","first-page":"398","volume":"35","author":"G Kerekes","year":"2008","unstructured":"Kerekes, G.  et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35, 398\u2013406 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011168_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.semarthrit.2008.08.005","volume":"39","author":"H Pieringer","year":"2009","unstructured":"Pieringer, H., Schumacher, S., Stuby, U. & Biesenbach, G. Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls. Semin. Arthritis Rheum. 39, 163\u2013169 (2009).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum2011168_CR52","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag, K. G.  et al. American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762\u2013784 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR53","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J. S.  et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964\u2013975 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","volume":"6","author":"ES Chan","year":"2010","unstructured":"Chan, E. S. & Cronstein, B. N. Methotrexate\u2014how does it really work? Nat. Rev. Rheumatol. 6, 175\u2013178 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum2011168_CR55","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi, H. K., Hernan, M. A., Seeger, J. D., Robins, J. M. & Wolfe, F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359, 1173\u20131177 (2002).","journal-title":"Lancet"},{"issue":"Suppl.","key":"BFnrrheum2011168_CR56","first-page":"ii49","volume":"47","author":"N Goodson","year":"2008","unstructured":"Goodson, N. The mortality association with DMARD use in early inflammatory arthritis [abstract]. Rheumatology (Oxford) 47 (Suppl.), ii49 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2011168_CR57","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/S0140-6736(00)02222-4","volume":"355","author":"RB Landewe","year":"2000","unstructured":"Landewe, R. B., van den Borne, B. E., Breedveld, F. C. & Dijkmans, B. A. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 355, 1616\u20131617 (2000).","journal-title":"Lancet"},{"key":"BFnrrheum2011168_CR58","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","volume":"49","author":"SL Westlake","year":"2010","unstructured":"Westlake, S. L.  et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 49, 295\u2013307 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2011168_CR59","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1186\/ar2045","volume":"8","author":"VP van Halm","year":"2006","unstructured":"van Halm, V. P., Nurmohamed, M. T., Twisk, J. W., Dijkmans, B. A. & Voskuyl, A. E. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res. Ther. 8, R151 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2011168_CR60","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2383","volume":"10","author":"A Naranjo","year":"2008","unstructured":"Naranjo, A.  et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res. Ther. 10, R30 (2008).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2011168_CR61","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/art.22094","volume":"55","author":"S Suissa","year":"2006","unstructured":"Suissa, S., Bernatsky, S. & Hudson, M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum. 55, 531\u2013536 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR62","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1185\/030079908X261177","volume":"24","author":"MC Hochberg","year":"2008","unstructured":"Hochberg, M. C., Johnston, S. S. & John, A. K. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr. Med. Res. Opin. 24, 469\u2013480 (2008).","journal-title":"Curr. Med. Res. Opin."},{"key":"BFnrrheum2011168_CR63","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1136\/ard.2010.129916","volume":"70","author":"JD Greenberg","year":"2011","unstructured":"Greenberg, J. D.  et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 576\u2013582 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR64","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1002\/art.24040","volume":"58","author":"AB Reiss","year":"2008","unstructured":"Reiss, A. B.  et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages. Arthritis Rheum. 58, 3675\u20133683 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR65","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1194\/jlr.R600021-JLR200","volume":"48","author":"C Popa","year":"2007","unstructured":"Popa, C., Netea, M. G., van Riel, P. L., van der Meer, J. W. & Stalenhoef, A. F. The role of TNF-\u03b1 in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res. 48, 751\u2013762 (2007).","journal-title":"J. Lipid Res."},{"key":"BFnrrheum2011168_CR66","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/acr.20371","volume":"63","author":"C Barnabe","year":"2011","unstructured":"Barnabe, C., Martin, B. J. & Ghali, W. A. Systematic review and meta-analysis: Anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. (Hoboken) 63, 522\u2013529 (2011).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2011168_CR67","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/rheumatology\/keq316","volume":"50","author":"SL Westlake","year":"2011","unstructured":"Westlake, S. L.  et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 50, 518\u2013531 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2011168_CR68","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon, W. G.  et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor \u03b1 therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905\u20132912 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR69","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJM199007263230405","volume":"323","author":"B Levine","year":"1990","unstructured":"Levine, B., Kalman, J., Mayer, L., Fillit, H. M. & Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236\u2013241 (1990).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2011168_CR70","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/hrt.70.2.141","volume":"70","author":"DP Dutka","year":"1993","unstructured":"Dutka, D. P., Elborn, J. S., Delamere, F., Shale, D. J. & Morris, G. K. Tumour necrosis factor \u03b1 in severe congestive cardiac failure. Br. Heart J. 70, 141\u2013143 (1993).","journal-title":"Br. Heart J."},{"key":"BFnrrheum2011168_CR71","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A. & Willerson, J. T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133\u20133140 (2003).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR72","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann, D. L.  et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594\u20131602 (2004).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR73","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","volume":"116","author":"F Wolfe","year":"2004","unstructured":"Wolfe, F. & Michaud, K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. 116, 305\u2013311 (2004).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2011168_CR74","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/rheumatology\/kem212","volume":"46","author":"JR Curtis","year":"2007","unstructured":"Curtis, J. R.  et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-\u03b1 antagonists. Rheumatology (Oxford) 46, 1688\u20131693 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2011168_CR75","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00296-006-0215-3","volume":"27","author":"J Cole","year":"2007","unstructured":"Cole, J., Busti, A. & Kazi, S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor \u03b1 antagonists. Rheumatol. Int. 27, 369\u2013373 (2007).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum2011168_CR76","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","volume":"156","author":"S Setoguchi","year":"2008","unstructured":"Setoguchi, S.  et al. Tumor necrosis factor-\u03b1 antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am. Heart J. 156, 336\u2013341 (2008).","journal-title":"Am. Heart J."},{"key":"BFnrrheum2011168_CR77","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/art.23281","volume":"58","author":"J Listing","year":"2008","unstructured":"Listing, J.  et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum. 58, 667\u2013677 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR78","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/03009740903079321","volume":"38","author":"PA Klimiuk","year":"2009","unstructured":"Klimiuk, P. A., Sierakowski, S., Domyslawska, I. & Chwiecko, J. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 38, 439\u2013444 (2009).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum2011168_CR79","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/01.CIR.0000037521.71373.44","volume":"106","author":"D Hurlimann","year":"2002","unstructured":"Hurlimann, D.  et al. Anti-tumor necrosis factor-\u03b1 treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184\u20132187 (2002).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR80","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/art.20407","volume":"51","author":"C Gonzalez-Juanatey","year":"2004","unstructured":"Gonzalez-Juanatey, C.  et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor \u03b1 antibody. Arthritis Rheum. 51, 447\u2013450 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR81","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/ard.2006.063867","volume":"66","author":"WG Dixon","year":"2007","unstructured":"Dixon, W. G. & Symmons, D. P. What effects might anti-TNF\u03b1 treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF\u03b1 in cardiovascular pathophysiology. Ann. Rheum. Dis. 66, 1132\u20131136 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR82","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1001\/jama.2011.878","volume":"305","author":"DH Solomon","year":"2011","unstructured":"Solomon, D. H.  et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305, 2525\u20132531 (2011).","journal-title":"JAMA"},{"key":"BFnrrheum2011168_CR83","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen, S. B.  et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793\u20132806 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR84","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/ard.2009.119016","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery, P.  et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann. Rheum. Dis. 69, 510\u2013516 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR85","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/art.24308","volume":"59","author":"C Gonzalez-Juanatey","year":"2008","unstructured":"Gonzalez-Juanatey, C.  et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor \u03b1 blocker therapy. Arthritis Rheum. 59, 1821\u20131824 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR86","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10067-009-1095-1","volume":"28","author":"G Kerekes","year":"2009","unstructured":"Kerekes, G.  et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin. Rheumatol. 28, 705\u2013710 (2009).","journal-title":"Clin. Rheumatol."},{"issue":"Suppl. 3","key":"BFnrrheum2011168_CR87","first-page":"388","volume":"62","author":"S Mathieu","year":"2010","unstructured":"Mathieu, S.  et al. Assessment of cardiovascular markers after 24 weeks of abatacept or rituximab therapy in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. 62 (Suppl. 3), 388 (2010).","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 3","key":"BFnrrheum2011168_CR88","first-page":"449","volume":"70","author":"H Raterman","year":"2011","unstructured":"Raterman, H.  et al. Rituximab alters the HDL particle from a pro-inflammatory into an anti-inflammatory property in good responding rheumatoid arthritis patients [abstract]. Ann. Rheum. Dis. 70 (Suppl. 3), 449 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR89","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone, E.  et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 56, 3896\u20133908 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR90","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.109.868158","volume":"120","author":"MJ Lewis","year":"2009","unstructured":"Lewis, M. J.  et al. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120, 417\u2013426 (2009).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR91","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2011)."},{"issue":"Suppl.","key":"BFnrrheum2011168_CR92","first-page":"S165","volume":"62","author":"R van Vollenhoven","year":"2010","unstructured":"van Vollenhoven, R.  et al. Long-term safety of rituximab: follow-up of the rheumatoid arthritis clinical trials and retreatment population [abstract]. Arthritis Rheum. 62 (Suppl.), S165 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR93","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/art.20277","volume":"50","author":"MH Schiff","year":"2004","unstructured":"Schiff, M. H.  et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum. 50, 1529\u20131531 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR94","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","volume":"117","author":"I Ikonomidis","year":"2008","unstructured":"Ikonomidis, I.  et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117, 2662\u20132669 (2008).","journal-title":"Circulation"},{"key":"BFnrrheum2011168_CR95","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini, R. N.  et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54, 2817\u20132829 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR96","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese, M. C.  et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968\u20132980 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR97","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3109\/s10165-010-0279-5","volume":"20","author":"N Nishimoto","year":"2010","unstructured":"Nishimoto, N., Ito, K. & Takagi, N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod. Rheumatol. 20, 222\u2013232 (2010).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum2011168_CR98","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00296-009-1303-y","volume":"31","author":"SY Kawashiri","year":"2011","unstructured":"Kawashiri, S. Y.  et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol. Int. 31, 451\u2013456 (2011).","journal-title":"Rheumatol. Int."},{"issue":"Suppl. 3","key":"BFnrrheum2011168_CR99","first-page":"612","volume":"70","author":"M Moriyama","year":"2011","unstructured":"Moriyama, M.  et al. Tocilizumab increases serum lipids but does not promote atherosclerosis in patients with rheumatoid arthritis [abstract]. Ann. Rheum. Dis. 70 (Suppl. 3), 612 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR100","doi-asserted-by":"publisher","first-page":"e14328","DOI":"10.1371\/journal.pone.0014328","volume":"5","author":"O Schultz","year":"2010","unstructured":"Schultz, O.  et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 5, e14328 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2011168_CR101","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/ard.2010.132845","volume":"70","author":"A Ogata","year":"2011","unstructured":"Ogata, A.  et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann. Rheum. Dis. 70, 1164\u20131165 (2011).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 3","key":"BFnrrheum2011168_CR102","first-page":"462","volume":"70","author":"E Zampeli","year":"2011","unstructured":"Zampeli, E.  et al. Treatment with tocilizumab improved arterial function in rheumatoid arthritis: a 6-month pilot study [abstract]. Ann. Rheum. Dis. 70 (Suppl. 3), 462 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR103","first-page":"609","volume":"70","author":"M Genovese","year":"2011","unstructured":"Genovese, M.  et al. Long-term safety of tocilizumab in rheumatoid arthritis clinical trials [abstract]. Ann. Rheum. Dis. 70, 609 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2011168_CR104","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2011)."},{"issue":"Suppl. 10","key":"BFnrrheum2011168_CR105","first-page":"S718","volume":"60","author":"R Fleischmann","year":"2009","unstructured":"Fleischmann, R.  et al. Safety and efficacy after 24 week dosing of the oral JAK inhibitor CP-690,550 as monotherapy in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum. 60 (Suppl. 10), S718 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR106","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer, J. M.  et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60, 1895\u20131905 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR107","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/acr.20494","volume":"63","author":"Y Tanaka","year":"2011","unstructured":"Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S. & Zwillich, S. H. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and inadequate response to methotrexate. Arthritis Care Res. (Hoboken) 63, 1150\u20131158 (2011).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2011168_CR108","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1002\/art.23992","volume":"58","author":"ME Weinblatt","year":"2008","unstructured":"Weinblatt, M. E.  et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309\u20133318 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR109","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1517\/13543784.17.5.641","volume":"17","author":"M Bajpai","year":"2008","unstructured":"Bajpai, M., Chopra, P., Dastidar, S. G. & Ray, A. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin. Investig. Drugs. 17, 641\u2013659 (2008).","journal-title":"Expert Opin. Investig. Drugs."},{"key":"BFnrrheum2011168_CR110","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","volume":"363","author":"ME Weinblatt","year":"2010","unstructured":"Weinblatt, M. E.  et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303\u20131312 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2011168_CR111","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/art.30114","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese, M. C.  et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 63, 337\u2013345 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2011168_CR112","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1161\/ATVBAHA.111.230847","volume":"31","author":"I Hilgendorf","year":"2011","unstructured":"Hilgendorf, I.  et al. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc Biol. 31, 1991\u20131999 (2011).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"BFnrrheum2011168_CR113","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1002\/art.22808","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon, W. G.  et al. Serious infection following anti-tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies Arthritis Rheum. 56, 2896\u20132904 (2007).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.168","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:28:26Z","timestamp":1684470506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2011.168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,15]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["BFnrrheum2011168"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2011.168","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,15]]}}}